|
2024
|
G/S
|
Pharmaceutical products for human use. |
|
2023
|
Invention
|
Vaccine against klebsiella pneumoniae. The present invention relates to novel immunogenic compoun... |
|
|
Invention
|
Crystalline adipic acid salt form of a ccr6 antagonist. The present invention relates to a crysta... |
|
|
Invention
|
Aryl- and heteroaryl-sulfonamide derivatives as ccr8 modulators. The present invention relates to... |
|
|
Invention
|
Klebsiella pneumoniae. The present invention relates to novel oligosaccharide-carrier protein con... |
|
|
Invention
|
Macrocyclic cftr modulators. The present invention relates to macrocyclic compounds of Formula (I... |
|
|
Invention
|
Crystalline form of (3s,7s,10r,13r)-13-benzyl-20-fluoro-7-isobutyl-n-(2-(3-methoxy-1,2,4-oxadiazo... |
|
|
Invention
|
Combination of macrocyclic cftr modulators with cftr correctors and / or cftr potentiators. The p... |
|
|
Invention
|
1 receptor modulators for use in the treatment of type 1 ifn mediated diseases. 11 receptor modul... |
|
|
Invention
|
Pharmaceutical combination comprising an anti-cd3 antibody and a cxcr3 antagonist. The present in... |
|
|
Invention
|
Deuterated compounds. The present disclosure provides deuterated compounds and their use as T-typ... |
|
|
Invention
|
Crystalline forms of sodium (5-(4-bromophenyl)-6-(2-((5-bromopyrimidin-2-yl)oxy)ethoxy)pyrimidin-... |
|
|
Invention
|
Aprocitentan for the treatment of hypertension. The present invention concerns the compound aproc... |
|
|
Invention
|
Crystalline forms of a 4-pyrimidinesulfamide derivative aprocitentan.
The present invention conc... |
|
|
Invention
|
Thiazoloaryl-methyl substituted cyclic hydrazine-n-carboxamide derivatives. The present invention... |
|
|
G/S
|
Human pharmaceutical preparations for the prevention and treatment of auto-immune diseases, cardi... |
|
|
Invention
|
Tert-butoxycarbonyl)amino)-3-(diethoxyphosphoryl)propanoic acid or of phosphonate derivatives the... |
|
2022
|
Invention
|
2,4,6,7-tetrahydro-pyrazolo[4,3-d]pyrimidin-5-one derivatives and related compounds as c5a recept... |
|
|
G/S
|
Pharmaceutical and veterinary products, namely, vaccines, and pharmaceutical and veterinary prepa... |
|
|
Invention
|
Clazosentan disodium salt, its preparation and pharmaceutical compositions comprising the same. T... |
|
|
Invention
|
N-substituted indole derivatives.
The present invention relates to derivatives of formula (I)
... |
|
|
Invention
|
Ccr6 receptor modulators. The present invention relates to compounds of Formula (I), their synthe... |
|
|
Invention
|
Ccr6 receptor modulators.
The present invention relates to compounds of Formula (I), their synth... |
|
|
G/S
|
Pharmaceutical preparations for human use. |
|
|
G/S
|
Human pharmaceuticals for the prevention or treatment of auto-immune diseases, pulmonary diseases... |
|
|
G/S
|
Human pharmaceutical preparations for the prevention and treatment of viral diseases, autoimmune ... |
|
|
Invention
|
Vaccine against klebsiella pneumoniae. Klebsiella pneumoniae bacteria. |
|
|
Invention
|
A process for the synthesis of 4-((r)-2-{[6-((s)-3-methoxy-pyrrolidin-1-yl)-2-phenyl- pyrimidine-... |
|
|
G/S
|
Préparations pharmaceutiques destinées à la prévention ou au traitement des maladies cardiovascul... |
|
|
G/S
|
Pharmaceutical preparations intended for the prevention or treatment of cardiovascular diseases, ... |
|
|
G/S
|
Pharmaceutical preparations intended for the prevention or
treatment of cardiovascular diseases,... |
|
|
G/S
|
Human pharmaceutical preparations for the prevention and treatment of viral diseases, auto-immune... |
|
|
G/S
|
Human pharmaceutical preparations for the prevention and treatment of cardiovascular and pulmonar... |
|
|
Invention
|
Triazolyl-methyl substituted alpha-d-galactopyranoside derivatives.
The present invention relate... |
|
|
Invention
|
Triazolyl-methyl substituted alpha-d-galactopyranoside derivatives. The present invention relates... |
|
|
Invention
|
Hydroxyheterocycloalkane-carbamoyl derivatives.
The present invention relates to compounds of Fo... |
|
|
Invention
|
A crystalline form of (4-methyl-2-[1,2,3]triazol-2-yl-phenyl)-[(r)-3-(3-[1,2,3]triazol-2-yl-benzy... |
|
|
Invention
|
Crystalline form of a piperazinyl-thiazole derivative.
The invention relates to a crystalline fo... |
|
|
G/S
|
Produits pharmaceutiques à usage humain pour le traitement de la maladie de Fabry et des symptôme... |
|
|
G/S
|
Pharmaceutical preparations for human use for the treatment
of Fabry disease and the symptoms an... |
|
2021
|
G/S
|
Providing educational information about courses, classes and workshops relating to sleep disorder... |
|
|
Invention
|
A stable crystalline hydrate of clazosentan disodium salt.
The present invention relates to a st... |
|
|
Invention
|
Galectin-3 inhibiting 2-hydroxycycloalkane-1-carbamoyl derivatives.
The present invention relate... |
|
|
Invention
|
Spiro derivatives of alpha-d-galactopyranosides.
The present invention relates to compounds of F... |
|
|
G/S
|
Pharmaceutical preparations for human use for the treatment of Fabry disease and symptoms and seq... |
|
|
Invention
|
Macrocycles as cftr modulators.
The present invention relates to macrocyclic compounds of Formul... |
|
|
Invention
|
Macrocycles as cftr modulators. The present invention relates to macrocyclic compounds of Formula... |
|
|
Invention
|
Cyclobutyl-urea derivatives.
The invention relates to compounds of Formula (I)
The invention r... |
|
|
Invention
|
Azetidin-3-ylmethanol derivatives as ccr6 receptor modulators.
The present invention relates to ... |
|
|
Invention
|
Spirourea derivatives.
The invention relates to compounds of Formula (I)
The invention relates... |
|
|
Invention
|
Medical use of daridorexant.
The invention relates to daridorexant: Formula (I) or drochloric ac... |
|
2020
|
G/S
|
Electronic publications (downloadable) in the field of
medical tests which are used for identify... |
|
|
G/S
|
Publications électroniques sous forme de questionnairres dans le domaine des tests médicaux qui s... |
|
|
G/S
|
Downloadable electronic publications in the nature of newsletters and test results in the nature ... |
|
|
Invention
|
Combination of an azetidine lpa1 receptor antagonist with pirfenidone and/or nintedanib for use i... |
|
|
Invention
|
Pharmaceutical compositions comprising n-[1-(5-cyano-pyridin-2-ylmethyl)-1h-pyrazol-3-yl]-2-[4-(1... |
|
|
G/S
|
Human pharmaceutical preparations. |
|
|
G/S
|
Pharmaceutical preparations for the prevention or treatment of inflammatory diseases and inflamma... |
|
|
G/S
|
Pharmaceutical preparations for humans for the prevention and treatment of cardiovascular disease... |
|
|
G/S
|
Pharmaceutical preparations for human beings. |
|
|
G/S
|
Préparations pharmaceutiques pour le traitement des hémorragies cérébrales et leurs séquelles. |
|
|
G/S
|
Pharmaceutical preparations for treatment of cerebral hemorrhages and their sequelae |
|
|
G/S
|
Pharmaceutical preparations for treatment of cerebral
hemorrhages and their sequelae. |
|
|
Invention
|
2-hydroxycycloalkane-1-carbamoyl derivatives.
The present invention relates to compounds of Form... |
|
|
Invention
|
(hetero)aryl-methyl-thio-beta-d-galactopyranoside derivatives.
The present invention relates to ... |
|
|
Invention
|
(2-acetamidyl)thio-beta-d-galactopyranoside derivatives.
The present invention relates to compou... |
|
|
G/S
|
Pharmaceutical preparations for prevention or treatment of
cardiovascular diseases, hypertension... |
|
|
G/S
|
Préparations pharmaceutiques pour la prévention et le traitement des maladies cardiovasculaires, ... |
|
2019
|
G/S
|
Pharmaceutical preparations for the prevention or treatment of neurological disorders, diseases a... |
|
|
Invention
|
Clostridium difficile . Clostridium difficile bacteria. |
|
|
G/S
|
Pharmaceutical preparations for the treatment of cardiovascular diseases, hypertension, vasospasm... |
|
|
G/S
|
Pharmaceutical preparations for the treatment of cardiovascular diseases, hypertension, brain hae... |
|
|
G/S
|
Pharmaceutical preparations for the prevention or treatment of cardiovascular diseases, hypertens... |
|
|
G/S
|
Pharmaceutical products for human use for the treatment of Fabry disease and symptoms and sequela... |
|
|
G/S
|
Pharmaceutical products for human use for the treatment of
Fabry disease and symptoms and sequel... |
